Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for persistent diabetic macular oedema after prior anti-VEGF treatment
ACTRN12614001307695Phase 4Recruiting
- Sponsor
- DeepSeq.AI
- Start
- Jul 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in diabetic macular edema (DME), sponsored by DeepSeq.AI. Primary endpoint: No increase in macular thickness on Spectral Domain Optical Coherence Tomography. Started Jul 2014; status: recruiting.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ACTRN12614001307695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614001307695.